The price of this formulation was set at 27 yen per 0.35 ml, based on the price of diquafosol sodium (Diquas®), which was developed by Santen as a de novo treatment for dry eye by increasing mucin secretion via activation of P2Y2 receptors in corneal epithelium (Nakamura et al., 2012). This evidence concerns the gene MUC5AC and dry eye syndrome.